A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Passive immunization against misfolded toxic proteins is a promising approach to treat neurodegenerative disorders. For effective immunotherapy against Alzheimer’s disease, recent clinical data indicate that monoclonal antibodies directed against the amyloid-β peptide should be administered before the onset of symptoms associated with irreversible brain damage. It is therefore critical to develop technologies for continuous antibody delivery applicable to disease prevention. Here, we addressed this question using a bioactive cellular implant to deliver recombinant anti-amyloid-β antibodies in the subcutaneous tissue. An encapsulating device permeable to macromolecules supports the long-term survival of myogenic cells over more than 10 months in immunocompetent allogeneic recipients. The encapsulated cells are genetically engineered to secrete high levels of anti-amyloid-β antibodies. Peripheral implantation leads to continuous antibody delivery to reach plasma levels that exceed 50 µg/ml. In a proof-of-concept study, we show that the recombinant antibodies produced by this system penetrate the brain and bind amyloid plaques in two mouse models of the Alzheimer’s pathology. When encapsulated cells are implanted before the onset of amyloid plaque deposition in TauPS2APP mice, chronic exposure to anti-amyloid-β antibodies dramatically reduces amyloid-β 40 and amyloid-β 42 levels in the brain, decreases amyloid plaque burden, and most notably, prevents phospho-tau pathology in the hippocampus. These results support the use of encapsulated cell implants for passive immunotherapy against the misfolded proteins, which accumulate in Alzheimer’s disease and other neurodegenerative disorders. Passive immunization against toxic misfolded proteins could offer protection against neurodegenerative disease. Lathuilière et al . report the development of a retrievable device to encapsulate cells secreting recombinant anti-amyloid-β antibodies. When implanted in mouse models of Alzheimer’s disease, the system delivers antibodies to the brain and reduces amyloid and tau pathologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“…a The induced amyloid-b 42 production leads to intraneuronal amyloid-b accumulation at 1.5 months and amyloid plaque deposition after only 2 months (Oakley et al. , 2006). n / a t i c l / 139 To model the secondary prevention of Alzheimer’s disease, age-matched cohorts of 5XFAD mice were implanted…”
BackgroundInfluentialBard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 2×
“enhance phagocytosis by mouse microglial cells, a mechanism that has been proposed to mediate the clearance of amyloid plaques (Bard et al. , 2000; Bohrmann et al. , 2012; Demattos et al. , 2012).”
BackgroundTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 2×
“prevention) to better potentiate therapeutic effects (Doody et al., 2014; Salloway et al., 2014).”
ResultPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 1×
“…have / 5 / 1587 / 2468738 shown that the systemic administration of anti-amyloid-b antibodies can decrease brain amyloid burden in preclinical Alzheimer’s disease models (Bard et al. , 2000, 2003; DeMattos et al. , 2001; Wilcock et al. , 2004 a , b ; Buttini et al. , 2005; Adolfsson et al. , 2012).”
BackgroundOddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780
Niewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., Rueger, P., Stracke, J. O., Lau, W., Tissot, A. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2013.10.061 · Cited by 622 · cited 1×
“The glycosylation profile of the mAb-11 synthesized in C2C12 myoblasts is comparable to standard material produced by myeloma or HEK293 cells (Lathuiliere et al. , 2014 a ).”
MethodSelf-citationSperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70015-7 · Cited by 512 · cited 2×
“…at the early presymptomatic stage (secondary prevention) to better potentiate therapeutic effects (Doody However, bolus administration of anti-amyloid-b antibodies may aggravate dose-dependent adverse effects such as amyloid-related imaging abnormalities (ARIA) (Sperling et al. , 2012).”
BackgroundBohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448 · cited 5×
“enhance phagocytosis by mouse microglial cells, a mechanism that has been proposed to mediate the clearance of amyloid plaques (Bard et al. , 2000; Bohrmann et al. , 2012; Demattos et al. , 2012).”
BackgroundMethodInfluentialSelf-citationA Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
DeMattos, R. B., Lu, J., Tang, Y., Racke, M. M., DeLong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.10.029 · Cited by 442 · cited 5×
“enhance phagocytosis by mouse microglial cells, a mechanism that has been proposed to mediate the clearance of amyloid plaques (Bard et al. , 2000; Bohrmann et al. , 2012; Demattos et al. , 2012).”
BackgroundMethodInfluential
Cited by
Cell encapsulation: Overcoming barriers in cell transplantation in diabetes and beyond
Farina, M., Alexander, J. F., Thekkedath, U., Ferrari, M., & Grattoni, A. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.018 · Cited by 192
TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance
Xiang, X., Werner, G., Bohrmann, B., Liesz, A., Mazaheri, F., Capell, A., Feederle, R., Knuesel, I., Kleinberger, G., & Haass, C. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606370 · Cited by 183
“For in vitro and ex vivo phagocytosis assay, the following antibodies were used: rat monoclonal antibody 2D8 against Ab1–16 (Shirotani et al, 2007), rabbit polyclonal antibody 6687 against cytosolic domain of APP (Capell et al, 2000), mouse IgG2a isotype control (Sigma-Aldrich), and mouse monoclonal mAb11 (IgG2a (Bohr…”
InfluentialSelf-citationFibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models
Sebastian Monasor, L., Müller, S. A., Colombo, A. V., Tanrioever, G., König, J., Roth, S., Liesz, A., Berghofer, A., Piechotta, A., Prestel, M., et al. (2020) · eLife · doi:10.7554/elife.54083 · Cited by 147
APOE Antibody Inhibits Aβ‐Associated Tau Seeding and Spreading in a Mouse Model
Gratuze, M., Jiang, H., Wang, C., Xiong, M., Bao, X., & Holtzman, D. M. (2022) · Annals of Neurology · doi:10.1002/ana.26351 · Cited by 41
Lathuiliere, A., Vernet, R., Charrier, E., Urwyler, M., Von Rohr, O., Belkouch, M.-C., Saingier, V., Bouvarel, T., Guillarme, D., Engel, A., et al. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.017 · Cited by 14
Metadata
- Authors
- Lathuilière, A., Laversenne, V., Astolfo, A., Kopetzki, E., Jacobsen, H., Stampanoni, M., Bohrmann, B., Schneider, B. L., & Aebischer, P.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-03-08
- Volume
- 139
- Issue
- 5
- Pages
- 1587-1604
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2297250143
- Cited by
- 46
- References
- 23
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.